Welcome to Metabiomics.com
Metabiomics is developing a non-invasive stool test for the early detection of colon polyps and colorectal cancer based an advanced interrogation of the human gut microbiome.
Metabiomics is an early stage molecular diagnostics company that is developing in-vitro diagnostics, screening tests, and health assays that leverage breakthroughs in next-generation DNA sequencing, computational systems biology, and human microbiome sciences.
Investor Resources and News
Metabiomics has developed strategies for rapid commercialization and growth built on a strong technology foundation and a management team with extensive and diverse experience. Please contact us directly for more information on available investment opportunities.
Metabiomics expands management team and advisory board to include Dr. Louis Korman, Dr. Robert Hardi, Dr. Jeffrey Baybick and Dr. Paul DeRidder. The new team members have extensive clinical research, healthcare, gastroenterology, pathology and international business development experience.
Clinical Research News and Resources
Metabiomics conducts microbiome systems biology, molecular diagnostics, and gastroenterology clinical research in collaboration with leading medical institutions and strategic partners across the North America, Europe and Asia. Please contact us directly to explore strategic alliance, collaboration, and technology licensing opportunities.
Clinical Collaborator Resources
- Cloud Portal Access (coming soon)
- Metabiomics Neoplasia Clinical Research Study – Clinicaltrials.gov
- Subscribe to Newsletter
- Contact Us
Metabiomics launches a new IRB approved microbiome colon cancer diagnostics clinical research study titled “Metabiomics Neoplasia Clinical Research Study,” The study is also often referred to as MB-01.
MultiTag™ Sequencing Patent Award in US Clears Path for Metabiomics Colorectal Cancer and Gastrointestinal Disease Molecular Diagnostic Clinical Trials
The award today of US Patent 8,603,749, MutiTag Sequencing for Ecogenomics Analysis, represents a major milestone for Metabiomics by providing exclusive rights to fundamental next-generation DNA sequencing analysis technology for multiplexed ‘barcoded” sequencing of multiple samples in high-throughput analyses in the field of gastrointestinal diagnostics and therapeutic biomarker discovery.